Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing novel adult retinal pigment epithelial stem ...

BrightFocus Foundation launches two national public service announcements encouraging eye exams to save sight from macular ...

During his tenure at Roche's Genentech, ophthalmologist Jason Ehrlich, M.D., Ph.D., supported the development of the ...

Ollin Biosciences has officially launched with $100 million in funding to advance a pipeline of therapies for ...

An analysis of pivotal phase 3 trials shows supplements to arrest age-related macular degeneration have no effect on ...

LumiThera's key innovation is a device for use by ophthalmologists that improves vision and slows its loss, with a focus on ...

OLN324 targets both VEGF and Ang2, the same mechanism of action as Roche’s Vabysmo, the Swiss giant’s multi-blockbuster ...

A new study published in the Journal of American Medical Association found that patients with exudative age-related macular ...

Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and efficacy in nAMD patients receiving four initial ...

The use of anticoagulants or antiplatelets was linked to a higher risk of intraocular hemorrhage requiring vitrectomy in ...

While pivotal research on therapies for neovascular age-related macular degeneration (nAMD) and geographic atrophy (GA) ...